Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-12-18
DOI
10.3389/fonc.2019.01394
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
- (2019) Jingsi Dong et al. Frontiers in Pharmacology
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of NF-κB Signaling Reduces the Stemness Characteristics of Lung Cancer Stem Cells
- (2018) Norashikin Zakaria et al. Frontiers in Oncology
- Cancer Stem Cell Metabolism and Potential Therapeutic Targets
- (2018) Vusala Snyder et al. Frontiers in Oncology
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
- (2018) Michael E. Goldberg et al. PLoS One
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
- (2017) Baohui Han et al. LUNG CANCER
- Promising cancer drugs may speed tumours in some patients
- (2017) Heidi Ledford NATURE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment
- (2017) Pedro M. Aponte et al. Stem Cells International
- Targeting Lung Cancer Stem Cells: Research and Clinical Impacts
- (2017) Norashikin Zakaria et al. Frontiers in Oncology
- Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition
- (2017) Verena Tiran et al. Scientific Reports
- Three-dimensional cell culture model utilization in cancer stem cell research
- (2016) Zofia F. Bielecka et al. BIOLOGICAL REVIEWS
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells
- (2016) Li Lin et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Prognostic significance of stem cell-related marker expression and its correlation with histologic subtypes in lung adenocarcinoma
- (2016) Eunhyang Park et al. Oncotarget
- Aldehyde dehydrogenase 1A1 in stem cells and cancer
- (2016) Hiroyuki Tomita et al. Oncotarget
- Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors
- (2015) Mauricio Rodriguez-Torres et al. CLINICAL & EXPERIMENTAL METASTASIS
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- A Reliable Parameter to Standardize the Scoring of Stem Cell Spheres
- (2015) Xiaochen Zhou et al. PLoS One
- 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
- (2014) J. Vansteenkiste et al. ANNALS OF ONCOLOGY
- Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity
- (2014) Lourdes Cortes-Dericks et al. BMC CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Isolation, cultivation and identification of human lung adenocarcinoma stem cells
- (2014) DE-GENG ZHANG et al. Oncology Letters
- Identification and Characterization of Cells with Cancer Stem Cell Properties in Human Primary Lung Cancer Cell Lines
- (2013) Ping Wang et al. PLoS One
- The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer
- (2013) Muhammad Alamgeer et al. THORAX
- Pluripotency transcription factors and cancer stem cells: small genes make a big difference
- (2013) Anfei Liu et al. Chinese Journal of Cancer
- Flow cytometry in cancer stem cell analysis and separation
- (2012) Burkhard Greve et al. CYTOMETRY PART A
- Tumor Heterogeneity: Mechanisms and Bases for a Reliable Application of Molecular Marker Design
- (2012) Salvador J. Diaz-Cano INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer
- (2011) Christoph Kahlert et al. BMC CANCER
- Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy
- (2010) James P. Sullivan et al. CANCER AND METASTASIS REVIEWS
- Aldehyde Dehydrogenase Activity Selects for Lung Adenocarcinoma Stem Cells Dependent on Notch Signaling
- (2010) J. P. Sullivan et al. CANCER RESEARCH
- Side Population is Not Necessary or Sufficient for a Cancer Stem Cell Phenotype in Glioblastoma Multiforme
- (2010) Kate W. R. Broadley et al. STEM CELLS
- Lung Cancer Stem Cell: New Insights on Experimental Models and Preclinical Data
- (2010) Caroline Rivera et al. Journal of Oncology
- Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis
- (2010) Ryan Morrison et al. Journal of Oncology
- A powerful and flexible linear mixed model framework for the analysis of relative quantification RT-PCR data
- (2009) Juan Pedro Steibel et al. GENOMICS
- Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer
- (2009) F. Jiang et al. MOLECULAR CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started